Stratton, Clamydia & Porphyria

[Guest guest]

Really interesting, this patent for a clamydia treatment protocol,

co-authored by Stratton:

http://spore.patentmatrix.com/projects/wncctc/Bio069/..%5CBOS%

5C6579854.html

His protocol combines several (from a list) of long term antibiotics

with anti-inflammatory agents.

Here's a very interesting quote: (seems to me, secondary porphyria

could be caused by any bacterial infection, not just chlamydia?)

The subject invention also pertains to a method for treating

porphyria caused by Chiamydia in an individual in need thereof,

comprising reducing the levels of active stage, latent stage and

elementary bodies of the pathogen from the individual and

administering one or more compounds which reduce adverse effects

associated with secondary porphyria. In one embodiment, the method

additionally comprises administering a compound which reduces the

adverse effects of porphyrins associated with porphyria. In a

particular embodiment, the compound is cimetidine. This method can

also be valuably combined with additional steps, including at least

one of administering antioxidants; orally administering activated

charcoal; administering a ihigh carbohydrate diet regimen;

administering hydroxychloroquine; administering benzodiazepine

drugs; performing hemodialysis; performing plasmaphoresis; and

adminstering chelating agents; and administering intravenous

hematin.

(There's that cimetidine again.)

So what's the word on Stratton these days? I haven't really followed

him much. I have to say, this treatment protocol is a lot more

sensible than most protocols I've seen. Is anyone using it yet? Have

the tests received FDA approval?

penny

Another excerpt. (This patent covers everything but the kitchen

sink.)

Diseases Associated with Chlamydial Infection

An association has been discovered between chronic Chlamydia

infection of body fluids and/or tissues with several disease

syndromes of previously unknown etiology in humans which respond to

unique antichlamydial regimens described herein. To date, these

diseases include Multiple Sclerosis (MS), Rheumatoid Arthritis (RA),

Inflammatory Bowel Disease (IBD), Interstitial Cystitis (IC),

Fibromyalgia (FM), Autonomic nervous dysfunction (AND, neural-

mediated hypotension); Pyoderma Gangrenosum (PG), Chronic Fatigue

(CF) and Chronic Fatigue Syndrome (CFS). Other diseases are under

investigation. Correlation between Chlamydia infection and these

diseases has only recently been established as a result of the

diagnostic methodologies and combination therapies described herein.

Based on this evidence, published evidence of an association between

atherosclerosis and Chlamydia (Grupta el al, Circulation 96:404-407

(1997)), and an understanding of the impact Chlamydia infections

have on infected cells and the immune systems, the inventors have

discovered a connection between Chlamydia and a broad set of

inflammatory, autoimmune, and immune deficiency diseases. Thus, the

invention describes methods for diagnosing and/or treating disease

associated with Chlamydia infection, such as autoimmune diseases,

inflammatory diseases and diseases that occur in immunocompromised

individuals by diagnosing and/or treating the Chlamydia infection in

an individual in need thereof, using any of the assays or therapies

described herein. Progress of the treatment can be evaluated

serologically, to determine the presence or absence of Chlamydia

using for example the diagnostic methods provided herein. and this

value can be compared to serological values taken earlier in the

therapy. Physical improvement in the conditions and symptoms

typically associated with the disease to be treated should also be

evaluated. Based upon these evaluating factors, the physician can

maintain or modify the antichlamydial therapy accordingly. For

example, the physician may change an agent due to adverse side-

effects caused by the agent, ineffectiveness of the agent, or for

other reason. When antibody titers rise during treatment then

alternate compounds should be substituted in order to achieve the

lower antibody titers that demonstrate specific susceptability of

the Chlamydia to the new regimen. A replacement or substitution of

one agent with another agent that is effective against the same life

stage of Chlamydia is desirable.

The therapies described herein can thus be used for the treatment of

acute and chronic immune and autoimmune diseases when patients are

demonstrated to have a Chlamydia load by the diagnostic procedures

described herein which diseases include, but are not limited to,

chronic hepatitis, systemic lupus erythematosus, arthritis,

thyroidosis, scleroderma, diabetes mellitus, Graves' disease,

Beschet's disease and graft versus host disease (graft rejection).

The therapies of this invention can also be used to treat any

disorders in which a chlamydial species is a factor or co-factor.

Thus, the present invention can be used to treat a range of

disorders in addition to the above immune and autoimmune diseases

when demonstrated to be associated with chlamydial infection by the

diagnostic procedures described herein; for example, various

infections, many of which produce inflammation as primary or

secondary symptoms, including, but not limited to, sepsis syndrome,

cachexia, circulatory collapse and shock resulting from acute or

chronic bacterial infection, acute and chronic parasitic and/or

infectious diseases from bacterial, viral or fungal sources, such as

a HIV, AIDS (including symptoms of cachexia, autoimmune disorders,

AIDS dementia complex and infections) can be treated, as well as

Wegners Granulomatosis.

Among the various inflammatory diseases, there are certain features

of the inflammatory process that are generally agreed to be

characteristic. These include fenestration of the microvasculature,

leakage of the elements of blood into the interstitial spaces, and

migration of leukocytes into the inflamed tissue. On a macroscopic

level, this is usually accompanied by the familiar clinical signs of

erythema, edema, tenderness (hyperalgesia), and pain. Inflammatory

diseases, such as chronic inflammatory pathologies and vascular

inflammatory pathologies, including chronic inflammatory pathologies

such as aneurysms, hemorrhoids, sarcoidosis, chronic inflammatory

bowel disease, ulcerative colitis, and Crohn's disease and vascular

inflammatory pathologies, such as, but not limited to, disseminated

intravascular coagulation, atherosclerosis, and Kawasaki's pathology

are also suitable for treatment by methods described herein. The

invention can also be used to treat inflammatory diseases such as

coronary artery disease, hypertension, stroke, asthma, chronic

hepatitis, multiple sclerosis, peripheral neuropathy, chronic or

recurrent sore throat, laryngitis, tracheobronchitis. chronic

vascular headaches (including migraines, cluster headaches and

tension headaches) and pneumonia when demonstrated to be

pathogenically related to Chlamydia infection.